Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by Backwardbladeon Dec 19, 2014 12:30pm
149 Views
Post# 23249330

RE:Tax loss selling

RE:Tax loss sellingI have been looking at this for a while, as a kind of side interest.  Upon reading the last results in November, I think your concerns for more dilution going forward are a genuine concern.  Just off the top of my head, they have 2 more quarters of operational capability, at over a million per quarter.  They will be short for the third quarter.  

If they successfully complete phase 2 on the achilles tendon they will need a lot of money to advance phase 3.  To complete this one alone cost over 1 mill.  

To risky untill more clarification is put forward on how money will be optained, and at what cost, I think.  

See below, for justifcation of my concerns.....straight from the website

Our consolidated financial statements have been prepared on a going concern basis which assumes that the
Company will continue to realize its assets and discharge its obligations and commitments in the normal course
of operations. At September 30, 2014, the Company had accumulated losses of $14,090,838 since incorporation
and expects to incur further losses in the development of its business, which casts substantial doubt about the
Company’s ability to continue as a going concern. At September 30, 2014, the Company had working capital of
$3,040,465. Additional working capital will be required for research and development along with general and
administrative expenses and to further our business plans. Our financial statements do not include any
adjustments relating to the recoverability and classification of recorded assets, or the amounts of and 10
classification of liabilities that might be necessary in the event that the Company cannot continue as a going
concern.
The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable
operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from
normal business operations when they come due. The Company has financed its operations to date through the
issuance of equity. The continued volatility in the financial equity markets may make it difficult to raise funds by
private placements of shares. There is no assurance that the Company will be successful with its financing
ventures. 
Bullboard Posts